EyeBio doubles the size of its Series A as anti-VEGF veterans seek new ways of treating retinal diseases
Retinal disease biotech EyeBio has doubled the size of its initial Series A raise from February 2022. With another $65 million, the biotech will further test its Wnt agonist and bring a second asset into the clinic next year, CEO David Guyer told Endpoints News on Tuesday morning.
The Series A extension arrives a few weeks after the field’s biggest confab, the American Academy of Ophthalmology annual meeting, and comes after a string of financing rounds that has buoyed other startups in the space.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.